{"nctId":"NCT00384930","briefTitle":"Study of Tadalafil Once-a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia","startDateStruct":{"date":"2006-08"},"conditions":["Benign Prostatic Hyperplasia"],"count":1058,"armGroups":[{"label":"1","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: placebo"]},{"label":"2","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: tadalafil"]},{"label":"3","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: tadalafil"]},{"label":"4","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: tadalafil"]},{"label":"5","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: tadalafil"]}],"interventions":[{"name":"tadalafil","otherNames":["LY450190","Cialis","IC351"]},{"name":"tadalafil","otherNames":["LY450190","Cialis","IC351"]},{"name":"tadalafil","otherNames":["LY450190","Cialis","IC351"]},{"name":"tadalafil","otherNames":["LY450190","Cialis","IC351"]},{"name":"placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Males, 45 years or older, with benign prostatic hyperplasia, including lower urinary tract symptoms for at least 6 months prior to Visit 1 and an International Prostate Symptom Score (IPSS) greater than or equal to 13 at Visit 2.\n* Agree not to use approved or experimental benign prostatic hyperplasia or erectile dysfunction treatments anytime during the study\n* Have not taken finasteride or dutasteride therapy, any other lower urinary tract symptom (LUTS) therapy or phosphodiesterase type 5 (PDE5) inhibitors for specified duration of time prior to Visit 2.\n* Have a prostate specific antigen (PSA) score within acceptable range defined for study or negative biopsy of the prostate for cancer within 12 months of Visit 1.\n\nExclusion Criteria:\n\n* History of urinary retention or lower urinary tract (bladder) stones 6 months before the start of the study\n* History of bladder outlet obstruction or urethral obstruction due to stricture, valves, sclerosis, or tumor.\n* History of cardiac conditions including angina requiring certain treatment with nitrates, heart disease or coronary conditions including myocardial infarction, bypass surgery, angioplasty or stent placement for a specified time before starting the study.\n* Certain neurological conditions associated with bladder problems or injuries to the brain or spinal cord within a specified time before starting the study.\n* Nitrate use","healthyVolunteers":false,"sex":"MALE","minimumAge":"45 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline to 12 Week Endpoint in International Prostate Symptom Score (IPSS): Primary Analysis","description":"Assesses the severity of BPH-LUTS and the response to therapy. The total score was derived by summing the scores of the responses to the 7 component questions. Scores range from 0 to 35; 0-7 Mildly symptomatic; 8-19 moderately symptomatic; 20-35 severely symptomatic.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.08","spread":"6.36"},{"groupId":"OG001","value":"17.30","spread":"5.97"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.25","spread":"6.17"},{"groupId":"OG001","value":"-4.92","spread":"5.67"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to 12 Week Endpoint in International Prostate Symptom Score (IPSS) (Irritative) Subscore","description":"Measures irritative symptoms over the past 4 weeks of the IPSS. IPSS irritative subscore is the sum of Questions 2, 4 and 7 of the IPSS questionnaire. Scores range from 1 (few irritative symptoms) to 5 (frequent irritative symptoms), thus the 3 questions of the irritative subscore range from 0 to 15.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.58","spread":"3.09"},{"groupId":"OG001","value":"7.78","spread":"2.86"},{"groupId":"OG002","value":"7.65","spread":"2.84"},{"groupId":"OG003","value":"7.88","spread":"2.67"},{"groupId":"OG004","value":"7.53","spread":"3.07"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.99","spread":"2.92"},{"groupId":"OG001","value":"-1.62","spread":"2.83"},{"groupId":"OG002","value":"-1.91","spread":"2.64"},{"groupId":"OG003","value":"-2.04","spread":"2.75"},{"groupId":"OG004","value":"-2.05","spread":"2.86"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to 12 Week Endpoint in International Prostate Symptom Score (IPSS) Voiding (Obstructive) Subscore","description":"Measures obstructive symptoms over the past 4 weeks of the IPSS. IPSS obstructive subscore is the sum of Questions 1, 3, 5 and 6 of the IPSS questionnaire. Scores range from 1 (few obstructive symptoms) to 5 (frequent obstructive symptoms), thus the 4 questions of the obstructive score range from 0 to 20.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.51","spread":"4.21"},{"groupId":"OG001","value":"9.71","spread":"4.16"},{"groupId":"OG002","value":"9.65","spread":"4.10"},{"groupId":"OG003","value":"9.88","spread":"3.87"},{"groupId":"OG004","value":"9.57","spread":"4.45"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.27","spread":"4.00"},{"groupId":"OG001","value":"-2.31","spread":"3.84"},{"groupId":"OG002","value":"-3.00","spread":"3.87"},{"groupId":"OG003","value":"-3.29","spread":"4.04"},{"groupId":"OG004","value":"-3.17","spread":"4.02"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to 12 Week Endpoint in International Prostate Symptom Score (IPSS) Question 7 (Nocturia)","description":"Measures nocturia (the need to get up at night to urinate) over the past 4 weeks. Scores range from 1 (few episodes of nocturia) to 5 (frequent episodes of nocturia).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.36","spread":"1.10"},{"groupId":"OG001","value":"2.37","spread":"1.31"},{"groupId":"OG002","value":"2.36","spread":"1.91"},{"groupId":"OG003","value":"2.36","spread":"1.15"},{"groupId":"OG004","value":"2.20","spread":"1.23"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.36","spread":"1.09"},{"groupId":"OG001","value":"-0.43","spread":"1.33"},{"groupId":"OG002","value":"-0.49","spread":"1.17"},{"groupId":"OG003","value":"-0.43","spread":"1.28"},{"groupId":"OG004","value":"-0.54","spread":"1.17"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to 12 Week Endpoint in International Prostate Symptom Score (IPSS) Quality of Life (QoL) Index","description":"Assessment of quality of life (QOL) by urinary symptoms, with scores ranging from 0 (delighted) to 6 (terrible).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.57","spread":"1.19"},{"groupId":"OG001","value":"3.69","spread":"1.19"},{"groupId":"OG002","value":"3.54","spread":"1.30"},{"groupId":"OG003","value":"3.55","spread":"1.23"},{"groupId":"OG004","value":"3.59","spread":"1.28"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.56","spread":"1.20"},{"groupId":"OG001","value":"-0.86","spread":"1.13"},{"groupId":"OG002","value":"-0.92","spread":"1.30"},{"groupId":"OG003","value":"-0.98","spread":"1.46"},{"groupId":"OG004","value":"-0.97","spread":"1.27"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to 12 Week Endpoint in Benign Prostatic Hyperplasia Impact Index (BII)","description":"Measures the impact that symptoms of BPH has on the patients well being. This questionnaire has 4 questions assessing the level of urinary discomfort and it's impact on the patients. Three questions range from 0 (no impact) to 4 (high impact); one question ranges from 0 (low impact) to 4 (high impact). The BII score ranges from 0 to 16.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.94","spread":"2.95"},{"groupId":"OG001","value":"4.73","spread":"2.95"},{"groupId":"OG002","value":"4.66","spread":"2.98"},{"groupId":"OG003","value":"4.86","spread":"2.98"},{"groupId":"OG004","value":"4.75","spread":"2.79"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.79","spread":"2.52"},{"groupId":"OG001","value":"-0.83","spread":"2.66"},{"groupId":"OG002","value":"-1.25","spread":"2.75"},{"groupId":"OG003","value":"-1.31","spread":"2.79"},{"groupId":"OG004","value":"-1.34","spread":"2.41"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Answer \"Yes\" to the Lower Urinary Tract Symptoms (LUTS) Global Assessment Question (LUTS-GAQ)","description":"LUTS-GAQ Question asks the participant if the treatment they have been on has improved their uninary symptoms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"109","spread":null},{"groupId":"OG001","value":"120","spread":null},{"groupId":"OG002","value":"139","spread":null},{"groupId":"OG003","value":"146","spread":null},{"groupId":"OG004","value":"138","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to 12 Week Endpoint in Peak Urinary Flow","description":"Measures the maximum flow rate of urine (measured in mL/s). This is a continuous parameter with positive numeric values.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.31","spread":"4.85"},{"groupId":"OG001","value":"9.97","spread":"4.09"},{"groupId":"OG002","value":"10.37","spread":"3.86"},{"groupId":"OG003","value":"9.93","spread":"3.77"},{"groupId":"OG004","value":"9.82","spread":"3.97"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.23","spread":"5.01"},{"groupId":"OG001","value":"1.50","spread":"4.56"},{"groupId":"OG002","value":"1.61","spread":"3.95"},{"groupId":"OG003","value":"1.69","spread":"4.46"},{"groupId":"OG004","value":"2.15","spread":"4.69"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to 12 Week Endpoint in International Index of Erectile Function (IIEF) EF Domain","description":"Measures erectile function over the past 4 weeks on Questions 1-5 and 15 (6 questions) of the International Index of Erecile Function (IIEF) questionnaire. Scores range from 0 (low/no erectile function) to 5 (high erectile function), thus the 6 questions of the IIEF-EF domain range from 0 to 30.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.26","spread":"7.95"},{"groupId":"OG001","value":"17.42","spread":"8.30"},{"groupId":"OG002","value":"15.29","spread":"8.13"},{"groupId":"OG003","value":"17.22","spread":"8.43"},{"groupId":"OG004","value":"16.28","spread":"8.05"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.78","spread":"6.32"},{"groupId":"OG001","value":"3.97","spread":"7.30"},{"groupId":"OG002","value":"6.56","spread":"9.43"},{"groupId":"OG003","value":"6.64","spread":"8.29"},{"groupId":"OG004","value":"7.44","spread":"8.42"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline to Week 12 in International Prostate Symptom Score (IPSS): Supportive Analysis","description":"Assesses the severity of BPH-LUTS and the response to therapy. The total score was derived by summing the scores of the responses to the 7 component questions. Scores range from 0 to 35; 0-7 Mildly symptomatic; 8-19 moderately symptomatic; 20-35 severely symptomatic.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.23","spread":"0.49"},{"groupId":"OG001","value":"-3.81","spread":"0.50"},{"groupId":"OG002","value":"-4.83","spread":"0.49"},{"groupId":"OG003","value":"-5.13","spread":"0.48"},{"groupId":"OG004","value":"-5.17","spread":"0.50"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6},"commonTop":["Headache","Dyspepsia","Back pain","Nasopharyngitis","Myalgia"]}}}